XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Castration-resistant Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Contact: Study coordinator (Susan Sharry) · susan.sharry@hci.utah.edu · 801-585-3453

Study leads

Umang Swami, MD
Principal Investigator
Huntsman Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma) · mCRPC (Metastatic Castration-resistant Prostate Cancer)

Abroad (travel likely)RecruitingPHASE2

Duarte, United States · Boston, United States

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer · Colorectal Cancer · Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Scottsdale, United States

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · San Francisco, United States

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Metastatic Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

London, United Kingdom